The organization filed several suits targeting pharmaceutical companies whom they alleged to have blocked competition over generic drug production and a class action law suit against Bristol-Myers Squibb, a pharmaceutical manufacturer, for alleged damages the company inflicted by delaying competition for BuSpar, a brand name anti-anxiety drug.